For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Arcturus Therapeutics, Inc.

Calculating rank

USPTO Granted Patents = 65

CIPO Patents = 2

EPO Patents = 17

Trademarks = 4

Forward Citations = 296

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Padmanabh Chivukula (54 out of 57 patents)

Joseph E Payne (34 out of 56 patents)

Kiyoshi Tachikawa (24 out of 27 patents)

4. Priya Prakash Karmali (19 out of 33 patents)

5. Steven Paul Tanis (13 out of 42 patents)

6. Yanjie Bao (11 out of 12 patents)

7. Daiki Matsuda (9 out of 9 patents)

8. Pattraranee Limphong (7 out of 7 patents)

9. Jesper Wengel (6 out of 8 patents)

10. Amit Sagi (5 out of 5 patents)

11. Arisa Cale (4 out of 4 patents)

12. Jared Henry Davis (4 out of 4 patents)

13. Sean Michael Sullivan (4 out of 4 patents)

14. Carlos Gustavo Perez-Garcia (3 out of 5 patents)

15. Christine Esau (3 out of 5 patents)

Core Competencies:

Nucleic Acid Vaccine

Lipid Formulation

RNA Delivery

Cationic Lipid

Therapeutic Oligomers

Immune Responses

RNA Nanoparticles

Gene Editing

Amino-LNA Oligonucleotides

Coronovirus Vaccines

Ornithine Transcarbamylase

Amyloidosis

65 patents: Sort by Forward Citations

1. 12723023 - Ionizable cationic lipids for RNA delivery (2026-09-01),

2. 12637422 - Ionizable cationic lipid for RNA delivery (2026-05-26),

3. 12533410 - Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines (2026-01-27),

4. 12527881 - Ionizable cationic lipid for RNA delivery (2026-01-20),

5. 12509698 - SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS (2025-12-30),

6. RE50681 - Ionizable cationic lipid for RNA delivery (2025-12-02),

7. 12398379 - Compositions and methods for treating ornithine transcarbamylase deficiency (2025-08-26),

8. 12390524 - Compositions and methods for inducing immune responses (2025-08-19),

9. 12351834 - Compositions and methods for the treatment of ornithine transcarbamylase deficiency (2025-07-08),

10. 12290567 - Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates (2025-05-06),

11. 12286395 - Method of synthesis of an ionizable cationic lipid (2025-04-29),

12. 12220485 - Method of making lipid-encapsulated RNA nanoparticles (2025-02-11),

13. 12220455 - Coronavirus vaccine compositions and methods (2025-02-11),

14. 12178921 - Method of lyophilizing lipid nanoparticles (2024-12-31),

15. 12083224 - Lipid particles for nucleic acid delivery (2024-09-10),

Company Overview

Arcturus Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in RNA therapeutics. The company focuses on developing innovative solutions in nucleic acid vaccines and RNA delivery systems, leveraging advanced lipid formulations and cationic lipids. Arcturus is dedicated to enhancing immune responses through its proprietary RNA nanoparticles and therapeutic oligomers, aiming to address a range of diseases through cutting-edge gene editing technologies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

65 Patents

#97 in San Diego, CA

#1,305 in California

#5,614 in US

#11,344 in the World

San Diego, CA, United States of America

Arcturus Therapeutics, Inc.

Forward Citations = 296

45 inventors:

Padmanabh Chivukula (54 out of 57 patents)

Joseph E Payne (34 out of 56 patents)

Kiyoshi Tachikawa (24 out of 27 patents)

4. Priya Prakash Karmali (19 out of 33 patents)

5. Steven Paul Tanis (13 out of 42 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Arcturus Therapeutics, Inc.. Retrieved from https://idiyas.com/company/arcturus-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…